DHT_logo.jpg
DHT Holdings, Inc. Business Update
April 11, 2024 16:15 ET | DHT Holdings, Inc.
HAMILTON, BERMUDA, April 11, 2024 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: For the first quarter of 2024, the Company estimates time...
download.png
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024 08:00 ET | Altamira Therapeutics Ltd
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new...
ONWARD_Logotype®_Red.png
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
April 09, 2024 01:00 ET | ONWARD Medical NV
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
download.png
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024 08:45 ET | Altamira Therapeutics Ltd
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
BICX.jpg
BioCorRx Reports Business Update for 2023
April 02, 2024 08:30 ET | BioCorRx Inc
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
logo_TRANSGENE.jpg
Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
March 27, 2024 12:45 ET | Transgene S.A.
Résultats annuels 2023 et point sur l’activité TG4050 : de nouveaux résultats attendus en 2024 sur l’actif phare de TransgeneLes autres programmes cliniques et de recherche et innovation...
logo_TRANSGENE.jpg
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
March 27, 2024 12:45 ET | Transgene S.A.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity...
image1 (1).png
Evaxion Announces Business Update and Full Year 2023 Financial Results
March 27, 2024 07:30 ET | Evaxion Biotech
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...
DHT_logo.jpg
DHT Holdings, Inc. Business Update
January 17, 2024 16:15 ET | DHT Holdings, Inc.
HAMILTON, BERMUDA, January 17, 2024 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: The Company estimates its P&L break-even level for the...
Celyad-Logo-Color.jpg
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
January 16, 2024 16:01 ET | Celyad Oncology SA
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...